Halozyme Therapeutics (HALO) Other Non Operating Income (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Other Non Operating Income data on file, last reported at $1.3 million in Q1 2026.

• On a quarterly basis, Other Non Operating Income fell 80.67% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $16.0 million, a 37.55% decrease from a year earlier, with the FY2025 full-year figure at $21.5 million, down 9.6% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $1.3 million, down from $2.4 million in the prior quarter.
• Over the last five years, Other Non Operating Income for HALO reached as high as $7.3 million in Q4 2024 and fell as low as -$945000.0 in Q2 2022.
• Historically, Other Non Operating Income has averaged $3.8 million across 5 years, with a median of $4.8 million in 2023.
• Across the five-year window, Other Non Operating Income sank 527.6% in 2022 and soared 646.65% in 2023, its largest moves.
• Year by year, Other Non Operating Income stood at $852000.0 in 2022, then soared by 529.11% to $5.4 million in 2023, then soared by 35.32% to $7.3 million in 2024, then plunged by 66.5% to $2.4 million in 2025, then tumbled by 45.76% to $1.3 million in 2026.
• Per Business Quant data, the three most recent Other Non Operating Income figures were $1.3 million in Q1 2026, $2.4 million in Q4 2025, and $5.3 million in Q3 2025.